Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Stopped early · Phase 1

Conditions studied: Melanoma

In brief

This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.

Key facts

Study ID

NCT01123304

Run by

Morphotek

People needed

18

Starts

2010-05-01

Expected to finish

2012-03-01

Last updated by the study team

2014-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed AJCC Stage IIIB, IIIC or IV melanoma with injectable metastases (in transit, intradermal, or subcutaneous nodules)
• Tumor accessible to intra-tumoral injections
• Cumulative tumor volume great enough to accept MORAb-028 injections for a given dose level, based on intent to inject at a concentration of 1 mg/cm3

You may not qualify if…

• Are candidates for curative surgical excision or lymphadenectomy
• Prior non-surgical treatment within 4 weeks
• Known central nervous system (CNS) tumor involvement or metastases
• Hypersensitivity to MORAb-028

Where it is running

• John Wayne Cancer Institute — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.